← All trials
NCT06445946
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2024
- Primary completion
- Dec 31, 2029
- Completion date
- Dec 31, 2030
- First posted
- Jun 6, 2024
- Last posted
- Aug 9, 2024
- Enrollment
- 1572
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ohio State UniversityLead sponsor
- Ohio State UniversitySponsor investigator
- Patient-Centered Outcomes Research InstituteCollaborator
- Ohio State UniversityOfficial
- George Washington UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.